The company has two divisions: Pharma, which focuses its activity on the development
of innovative drugs through the search for new applications for already-known
molecules, and Services and Reagents, which uses cell-based in vitro methods
to predict the efficacy, safety and mechanism of action of developing molecules.
Advancell's business model allows it to achieve substantial reductions in costs,
risks and the development time of a drug.
Advancell is a world leader in nanomedicine, the science that uses technologies
at the nanometric (less then a millionth of a millimeter) scale to diagnose,
treat and prevent diseases. The most advanced project is focused on nanomedicines
for the topical treatment of psoriasis and other skin diseases. In addition,
Advancell is developing a new "orphan drug" for Chronic Lymphocytic
Leukaemia and an adjuvant treatment for depression, which is currently in the
clinical phase II.
The Services and Reagents Unit develops and markets in vitro cell models with
a regulatory and/or predictive value. Our R&D efforts are focused on the
development of new in vitro cell-based models and kits targeting skin ADME/Tox
and skin biology. We are experts in epithelial and mucosal barrier models, as
well as in hepatic metabolism and toxicity. Our ready-to-use reagent line (www.cacoready.com)
is distributed all over Europe.
Our company is located in Barcelona's "Parc Científic" and
has research centres at Santiago de Compostela University and Hospital La Fe,